Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.

[1]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[2]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[3]  M. Toi,et al.  MDM2 in breast cancer , 1997, Breast cancer.

[4]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[5]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[6]  U. Bhalla,et al.  Emergent properties of networks of biological signaling pathways. , 1999, Science.

[7]  S. Sehgal,et al.  Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.

[8]  J. Engelman,et al.  Phosphoinositide 3-Kinase Catalytic Subunit Deletion and Regulatory Subunit Deletion Have Opposite Effects on Insulin Sensitivity in Mice , 2005, Molecular and Cellular Biology.

[9]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[10]  B. Vanhaesebroeck,et al.  Glucose-Potentiated Chemotaxis in Human Vascular Smooth Muscle Is Dependent on Cross-Talk Between the PI3K and MAPK Signaling Pathways , 2004, Circulation research.

[11]  G. Mills,et al.  Therapeutic potential of phosphoinositide 3-kinase inhibitors , 2004 .

[12]  G. Mills,et al.  Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[13]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[14]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Y. Xin,et al.  Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. , 2005, World journal of gastroenterology.

[16]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[17]  E. Wimmer,et al.  MAP Kinase Phosphatase As a Locus of Flexibility in a Mitogen-Activated Protein Kinase Signaling Network , 2022 .

[18]  木村 晃子.  Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines , 2005 .

[19]  K. Rosenzweig,et al.  Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Chi-Ying F. Huang,et al.  Ultrasensitivity in the mitogen-activated protein kinase cascade. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[22]  Peter J. Alaimo,et al.  Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. , 2004, Bioorganic & medicinal chemistry.

[23]  G. Mills,et al.  Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. , 1995, Cancer research.

[24]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[25]  D. Rawlings,et al.  Protein Kinase C βII Regulates Akt Phosphorylation on Ser-473 in a Cell Type- and Stimulus-specific Fashion*♦ , 2004, Journal of Biological Chemistry.

[26]  J. Woodgett,et al.  Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. , 1991, European journal of biochemistry.

[27]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[28]  D. Hallahan,et al.  Erratum: A specific antagonist of the p110δ catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction (Cancer Research (July 2004) 64 (4893-4899) , 2004 .

[29]  A. Gingras,et al.  Translational Control of the Antiapoptotic Function of Ras* , 2000, The Journal of Biological Chemistry.

[30]  S. Edlbacher,et al.  Über den Stoffwechsel der Tumoren. IV. Mitteilung. , 2022 .

[31]  K. Okkenhaug,et al.  Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.

[32]  C. Streuli,et al.  Autocrine Signalling Through erbB Receptors Promotes Constitutive Activation of Protein Kinase B/Akt in Breast Cancer Cell Lines , 2003, Breast Cancer Research and Treatment.

[33]  D. Hardie,et al.  Management of cellular energy by the AMP‐activated protein kinase system , 2003, FEBS letters.

[34]  G. Mills,et al.  In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  Lewis C Cantley,et al.  The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[37]  K. Kinzler,et al.  Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.

[38]  E. Solary,et al.  Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .

[39]  A. Godwin,et al.  Expression of constitutively activated EGFRvlll in non‐small cell lung cancer , 2003, Cancer science.

[40]  C. James,et al.  Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Warne,et al.  Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.

[42]  S. Watts,et al.  Upregulated function of phosphatidylinositol‐3‐kinase in genetically hypertensive rats: a moderator of arterial hypercontractility , 2005, Clinical and experimental pharmacology & physiology.

[43]  J. Testa,et al.  A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. , 1991, Science.

[44]  Alfonso Bellacosa,et al.  AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Mills,et al.  Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  C. Lindsley,et al.  Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. , 2005, Molecular cancer therapeutics.

[47]  A. Tefferi,et al.  FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. , 2004, Blood.

[48]  Dihua Yu,et al.  Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone , 2003, Cancer.

[49]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[50]  M. Birnbaum,et al.  Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.

[51]  T. Tsuruo,et al.  Phosphorylation of p27Kip1 at Threonine 198 by p90 Ribosomal Protein S6 Kinases Promotes Its Binding to 14-3-3 and Cytoplasmic Localization* , 2003, Journal of Biological Chemistry.

[52]  D. Hallahan,et al.  A Specific Antagonist of the p110δ Catalytic Component of Phosphatidylinositol 3′-Kinase, IC486068, Enhances Radiation-Induced Tumor Vascular Destruction , 2004, Cancer Research.

[53]  F. Agani,et al.  Vascular Endothelial Growth Factor Transcriptional Activation Is Mediated by Hypoxia-inducible Factor 1α, HDM2, and p70S6K1 in Response to Phosphatidylinositol 3-Kinase/AKT Signaling* , 2004, Journal of Biological Chemistry.

[54]  J. Buckner,et al.  NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[56]  Brian A. Hemmings,et al.  Protein Kinase Bα/Akt1 Regulates Placental Development and Fetal Growth* , 2003, Journal of Biological Chemistry.

[57]  C. Thompson,et al.  Putting the rap on Akt. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  E. Sausville,et al.  Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. , 2003, Molecular cancer therapeutics.

[59]  J. Testa,et al.  Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization , 2000, Cytogenetic and Genome Research.

[60]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[61]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[62]  J. Blenis,et al.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[63]  W. Kaelin,et al.  The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. , 2003, The New England journal of medicine.

[64]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[65]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[66]  Catherine L Nutt,et al.  Genetic Alterations of Phosphoinositide 3‐kinase Subunit Genes in Human Glioblastomas , 2004, Brain pathology.

[67]  G. Giaccone,et al.  Pleural mesothelioma: combined modality treatments , 2002 .

[68]  G. Mills,et al.  Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. , 2002, Cancer research.

[69]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[70]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[71]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[72]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[73]  E. Sausville,et al.  Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  M. Crackower,et al.  The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. , 2004, Journal of molecular and cellular cardiology.

[75]  Huan Yang,et al.  AKT/PKB signaling mechanisms in cancer and chemoresistance. , 2005, Frontiers in bioscience : a journal and virtual library.

[76]  K. Okkenhaug,et al.  Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. , 2005, Blood.

[77]  Chang Shin Park,et al.  Kinetic Analysis of Platelet-derived Growth Factor Receptor/Phosphoinositide 3-Kinase/Akt Signaling in Fibroblasts* , 2003, Journal of Biological Chemistry.

[78]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[79]  David J. Kwiatkowski,et al.  Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[80]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[81]  S. Nicosia,et al.  Phosphatidylinositol 3-Kinase/Akt Pathway Regulates Tuberous Sclerosis Tumor Suppressor Complex by Phosphorylation of Tuberin* , 2002, The Journal of Biological Chemistry.

[82]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[83]  Manuel Hidalgo,et al.  Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.

[84]  A. Bezjak,et al.  A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  L. Cantley,et al.  Phosphoinositide kinases. , 1998, Annual review of biochemistry.

[86]  E. Nånberg,et al.  Role of phosphoinositide 3OH‐kinase in autocrine transformation by PDGF‐BB * , 2001, Journal of cellular physiology.

[87]  Yan Shi,et al.  Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. , 2004, Anticancer research.

[88]  Jonathan A. Cooper,et al.  p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes* , 1997, The Journal of Biological Chemistry.

[89]  T. S. P. S.,et al.  GROWTH , 1924, Nature.

[90]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[91]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[92]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[93]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[94]  J. Cheng,et al.  Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas , 1998, Molecular carcinogenesis.

[95]  M. Nelson,et al.  Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers. , 1996, Cancer letters.

[96]  G. Mills,et al.  Molecular therapeutics: promise and challenges. , 2004, Seminars in oncology.

[97]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[98]  Marketa Zvelebil,et al.  Phosphoinositide 3-kinase signalling--which way to target? , 2003, Trends in pharmacological sciences.

[99]  J E Ferrell,et al.  The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes. , 1998, Science.

[100]  J. Condeelis,et al.  Over-expression of the p110β but not p110α isoform of PI 3-kinase inhibits motility in breast cancer cells , 2004 .

[101]  R. Nussbaum,et al.  Proliferative Defect and Embryonic Lethality in Mice Homozygous for a Deletion in the p110α Subunit of Phosphoinositide 3-Kinase* , 1999, The Journal of Biological Chemistry.

[102]  J. Groffen,et al.  c-K-ras mutations in human carcinomas occur preferentially in codon 12. , 1987, Oncogene.

[103]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[104]  Andrew D. Yates,et al.  A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer , 2005, Nature Genetics.

[105]  P. Therasse,et al.  Evaluation of response: new and standard criteria. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[106]  R. McLendon,et al.  Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas , 2004, Cancer Research.

[107]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[108]  S. Lowe,et al.  Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[109]  H. Rockman,et al.  Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. , 2005, Journal of the American College of Cardiology.

[110]  L. G. Koss,et al.  Cervical Cancer , 1981, Current Topics in Pathology.

[111]  Tobias Schmelzle,et al.  TOR, a Central Controller of Cell Growth , 2000, Cell.

[112]  P. Finan,et al.  Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. , 2003, Current opinion in pharmacology (Print).

[113]  P. Cohen,et al.  Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.

[114]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[115]  Mariano Provencio,et al.  Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype , 1999, Breast Cancer Research and Treatment.

[116]  X. Liu,et al.  246 Novel ATP-competitive Akt inhibitors slow the progression of tumors in vivo , 2004 .

[117]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[118]  Hongbing Zhang,et al.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. , 2003, The Journal of clinical investigation.

[119]  Jennifer Skeen,et al.  Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. , 2003, Genes & development.

[120]  M. Albert.  Faculty Opinions recommendation of The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. , 2002 .

[121]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[122]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[123]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[124]  G. Ruvkun,et al.  Phosphatidylinositol 3-Kinase Signaling Inhibits DAF-16 DNA Binding and Function via 14-3-3-dependent and 14-3-3-independent Pathways* , 2001, The Journal of Biological Chemistry.

[125]  Charis Eng,et al.  PTEN: One Gene, Many Syndromes , 2003, Human mutation.

[126]  Patrick E Carroll,et al.  Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression , 1999, Oncogene.

[127]  J. D. Weber,et al.  The ARF/p53 pathway. , 2000, Current opinion in genetics & development.

[128]  Tian Xu,et al.  Akt regulates growth by directly phosphorylating Tsc2 , 2002, Nature Cell Biology.

[129]  M. Berger,et al.  Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors , 2005, Cell cycle.

[130]  Careen K. Tang,et al.  Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. , 2000, Cancer research.

[131]  A. Robertson,et al.  PI 3-kinase p110β: a new target for antithrombotic therapy , 2005, Nature Medicine.

[132]  G. Mills,et al.  Mammalian target of rapamycin. , 2004, Seminars in oncology.

[133]  T. Pawson,et al.  Protein-protein interactions define specificity in signal transduction. , 2000, Genes & development.

[134]  P. Edwards,et al.  Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism , 1999, Oncogene.

[135]  P. Jänne,et al.  Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. , 2005, Journal of the National Cancer Institute.

[136]  B. Karlan,et al.  Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. , 2003, Cancer research.

[137]  Yong J. Lee,et al.  Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway , 2005, Oncogene.

[138]  K. Okkenhaug,et al.  Class I Phosphoinositide 3-Kinase p110β Is Required for Apoptotic Cell and Fcγ Receptor-mediated Phagocytosis by Macrophages* , 2003, Journal of Biological Chemistry.

[139]  P. Hammerman,et al.  Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival , 2003, Molecular and Cellular Biology.

[140]  P. Ell,et al.  Clinical role of positron emission tomography in oncology. , 2001, The Lancet. Oncology.

[141]  Takashi Kumagai,et al.  PTEN promoter is methylated in a proportion of invasive breast cancers , 2004, International journal of cancer.

[142]  G. Wilding,et al.  A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer , 2004, Clinical Cancer Research.

[143]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[144]  M. Pollak,et al.  Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells , 2004, International journal of cancer.

[145]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  G. Mills,et al.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.

[147]  José Meseguer,et al.  Pathway Logic: Symbolic Analysis of Biological Signaling , 2001, Pacific Symposium on Biocomputing.

[148]  J. Cheng,et al.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[149]  Stephen W. Michnick,et al.  PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3 , 2004, Nature Cell Biology.

[150]  Andrew D. Yates,et al.  Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.

[151]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[152]  J. Um,et al.  Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. , 2000, Leukemia research.

[153]  Rosemarie Mick,et al.  Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. , 2003, International journal of radiation oncology, biology, physics.

[154]  G. Powis,et al.  In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. , 1995, Anticancer research.

[155]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[156]  J. Downward,et al.  Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3‐kinase , 1998, The EMBO journal.

[157]  A. Wellstein,et al.  Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway , 2003, Oncogene.

[158]  Donglei Zhang,et al.  Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling , 2003, Oncogene.

[159]  G. Lubec,et al.  Tuberous sclerosis genes regulate cellular 14-3-3 protein levels. , 2003, Biochemical and biophysical research communications.

[160]  Zhijian Zhao,et al.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[161]  J. Penninger,et al.  Phosphatidylinositide 3-kinase gamma regulates key pathologic responses to cholecystokinin in pancreatic acinar cells. , 2004, Gastroenterology.

[162]  S. Volinia,et al.  Phosphatidylinositol 3-kinase: Structure and expression of the 110 kd catalytic subunit , 1992, Cell.

[163]  K. Theil,et al.  HER-2/neu amplification and overexpression in endometrial carcinoma. , 1999, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[164]  C. Arteaga,et al.  Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model. , 2004, International journal of clinical pharmacology and therapeutics.

[165]  R. K Srivastava,et al.  Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer , 2001, Oncogene.

[166]  A. Hoffmann,et al.  The I (cid:1) B –NF-(cid:1) B Signaling Module: Temporal Control and Selective Gene Activation , 2022 .

[167]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[168]  K. Sachs,et al.  Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data , 2005, Science.

[169]  L. Garcia-Segura,et al.  Estrogen receptor alpha forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain. , 2003, Brain research. Molecular brain research.

[170]  C. Compton,et al.  Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. , 2004, Cancer research.

[171]  B. Evers,et al.  Regulation of TRAIL Expression by the Phosphatidylinositol 3-Kinase/Akt/GSK-3 Pathway in Human Colon Cancer Cells* , 2002, The Journal of Biological Chemistry.

[172]  T. Dreyer,et al.  Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma , 2002, The Journal of pathology.

[173]  Pamela A. Silver,et al.  A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. , 2003, Cancer cell.

[174]  Prahlad T. Ram,et al.  Formation of Regulatory Patterns During Signal Propagation in a Mammalian Cellular Network , 2005, Science.

[175]  M. Tsao,et al.  Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[176]  Prahlad T. Ram,et al.  MAP Kinase Phosphatase As a Locus of Flexibility in a Mitogen-Activated Protein Kinase Signaling Network , 2002, Science.

[177]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[178]  W. Fiedler,et al.  Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO) , 2002, Leukemia.

[179]  K. Okkenhaug,et al.  Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. , 2006, Blood.

[180]  W. Friedrichs,et al.  Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[181]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.

[182]  A. Kral,et al.  Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .

[183]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.